The anti-TM4SF5 strategy may have therapeutic advantages for the treatment of metastatic CRC and HCC because it targets different pathways from the current therapeutics, and Ab27-hz9 could be exploited as a starting platform to establish anti-TM4SF5 strategy. This evidence concerns the gene TM4SF5 and hepatocellular carcinoma.